# Patrick M. Forde

Source: https://onco.cc/people/patrick-forde/  
OnCo record `patrick-forde` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led CheckMate 816, which established neoadjuvant chemo-immunotherapy for resectable lung cancer.

## Summary

Patrick M. Forde is Director of the Thoracic Oncology Clinical Research Program at Johns Hopkins Hospital and the Sidney Kimmel Comprehensive Cancer Center. He is known for pioneering neoadjuvant PD-1 blockade in resectable non-small-cell lung cancer, from a 2018 pilot study to leading the CheckMate 816 phase 3 trial that established neoadjuvant nivolumab plus chemotherapy as a standard. His selected papers report neoadjuvant PD-1 blockade in resectable lung cancer and neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. He also leads mesothelioma trials.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Thoracic Oncology Clinical Research Program
- Specialisms: Neoadjuvant immunotherapy; Lung cancer; Mesothelioma

## Sources

- Hopkins profile: https://www.hopkinsmedicine.org/profiles/details/patrick-forde
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Forde%20PM%5BAuthor%5D

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- institutions: [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://onco.cc/institutions/johns-hopkins/)
- trials: [CheckMate 816](https://onco.cc/trials/checkmate-816/)
- key papers: [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/patrick-forde.json